key: cord-0309086-8kiooirt authors: Salum, S. S.; Sheikh, M. A.; Hebestreit, A.; Kelm, S. title: Anti SARS-CoV2 seroprevalence in Zanzibar in 2021 before the Omicron wave date: 2022-04-26 journal: nan DOI: 10.1101/2022.04.23.22274199 sha: 399d019c1dcd62bc1c52d44f05e231a31adb5904 doc_id: 309086 cord_uid: 8kiooirt Objectives For Tanzania including Zanzibar, The development of the COVID-19 pandemic has remained unclear, since reporting cases was suspended during2020/21. The present study provides first data on the COVID-19 seroprevalence among Zanzibari before the omicron variant wave starting in late 2021. Design During August through October 2021 representative cross-sectional data were collected from randomly selected households in 120 wards of the two main islands, Unguja and Pemba. Participants voluntarily provided blood samples to test their sera for antibodies against SARS-CoV2 in a semiquantitative enzyme-linked immunosorbant assay (ELISA). Results 57% of the 2080 sera analysed were positive without significant differences between Unguja and Pemba or between rural and urban areas, similar to observations from other sub-Saharan Africa countries. Conclusions The antibody levels observed are most likely to previous infections with SARS-CoV2, since vaccination was basically not available before the survey. Therefore, this study provides first insight, how many Zanzibari have had COVID-19 before the Omicron variant. Further, it provides the appropriate basis for a follow-up survey addressing how this seroprevalence influenced the susceptibility to the Omicron variants, given harmonised methodologies are used. COVID-19 was declared as a global pandemic early 2020. Following first case reports in March (WHO, 2022) , Tanzania implemented protecHve measures. However, May 2020 Tanzania stopped reporHng COVID-19 cases to WHO and most restricHons were lijed 18 th May. In mid 2021 Tanzania resumed reporHng, including previously detected COVID-19 cases, re-sulHng in 33,836 confirmed cases and a death toll of 803 by 1 April 2022 (The United Republic of Tanzania, Ministry of Health, 2022). These data clearly show COVID-19 waves for April-June 2020, January-March 2021, June-August 2021 coinciding with the original, alpha and delta variants waves, as well as for omicron variants, December 2021 through March 2022, (The United Republic of Tanzania, Ministry of Health, 2022). Herd (or populaHon) immunity is achieved, if a sufficient proporHon of a populaHon has acquired immunity, through natural infecHon or vaccinaHon, to prevent further spread of the pathogen. To achieve this for COVID-19, vaccinaHon is the most efficient and preferred way, according to WHO (WHO, 2020) , although the proporHon that must be vaccinated to effect herd immunity is sHll not known. While several efficient vaccines have been produced, in most sub-Saharan Africa countries these have only become available late and in low numbers. Zanzibar began vaccinaHon July 2021 (Mikofu, 2021) and vaccinaHon coverage in Tanzania including Zanzibar is sHll around 5% (The United Republic of Tanzania, Ministry of Health, 2022). While confirmed COVID-19 cases correspond to only 0.5% of the populaHon, an unknown number of SARS-CoV2 infecHons must be expected. Seroprevalence of anH-SARS-CoV2 anHbodies can provide essenHal informaHon (Bobrovitz et al., 2021) . Therefore, this study was performed in 2021 providing first data of the COVID-19 seroprevalence among Zanzibari before the omicron variants wave started in November 2021. This cross-secHonal study was designed to provide representaHve seroprevalence data from the main islands, Unguja and Pemba. 120 of the total 388 wards (Shehias) were randomly selected covering urban and rural areas. 354 randomly selected households were visited from 28 th July through 20 th October 2021. All household members were enrolled, irrespec-Hve of their age or sex, as in a previous survey (Nyangasa et al., 2016) . All eligible parHcipants gave wrioen consent in an enHrely voluntary manner ajer all relevant informaHon had been provided in the local language. Venous blood samples were collected into clopng acHvaHon tubes and transported to the laboratory for processing. Following centrifugaHon serum was stored at -80!. The EUROIMMUN AnH-SARS-CoV-2 ELISA (IgG) kit provided a semi-quanHtaHve analysis de-tecHng human IgG anHbodies against S1 domain of SARS-CoV-2 spike protein indicaHng prior infecHons and has been recommended for seroprevalence surveys like this (Gededzha et al., 2021) . Using the calibrator of the kit, a raHo-based analysis (OD of sample/OD of calibrator) of the obtained data was performed to differenHate between negaHve (raHo below 0.8), posiHve (raHo above 1.1) and borderline cases. According to the manufacturer's informaHon, this kit displayed a posiHve agreement of 90% (95%CI=73.5%-97.9%), counHng borderlines as negaHve, and a negaHve agreement of 100.0% (95%CI=95.5%-100.0%). UnHl now, the frequency of SARS-CoV-2 infecHons causing COVID-19 in Tanzania has been unknown. Seroprevalence provides important informaHon how many individuals were exposed to SARS-CoV-2 before sampling. This study is the first report on anH-SARS-CoV-2 sero-2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 26, 2022. ; https://doi.org/10.1101/2022.04.23.22274199 doi: medRxiv preprint prevalence in Zanzibar populaHon. In total, 2,080 parHcipants (66.2% of 3,143) from 349 (98.6%) households of this survey provided blood samples, with 2,054 serum samples being tested for anH-SARS-CoV-2 IgG; 57% of these samples were posiHve. Since vaccinaHon against Covid-19 basically had not been available to parHcipants, the anHbodies detected are likely to be induced by preceding SARS-CoV-2 infecHon(s) during COVID-19 waves (The United Republic of Tanzania, Ministry of Health, 2022). Seroprevalence was relaHvely evenly distributed and only minor differences were observed (Table 1 ) without significant differences between Unguja and Pemba. On Unguja, the seroprevalence observed in urban districts Magharibi and Mjini was lower, whereas on Pemba the lowest was in Micheweni, a rural district (Table 1) . Prevalence was slightly higher in males compared to the female parHcipants. The highest seroprevalence was observed in adolescents (Table 2 ). In summary, this first populaHon-based survey uncovered widespread SARS-CoV-2 seroposi-Hvity across all districts of Zanzibar prior to the onset of the current Omicron-dominated wave. Overall, seroprevalences observed are similar to those observed in other sub-Sahara Africa countries (Lewis et al., 2022) . At present, this level of seroprevalence cannot be considered as herd immunity, since it is uncertain, how anHbody levels correlate with virus neutralisaHon, protecHon against re-in-fecHon, symptomaHc and asymptomaHc cases (Centers for Disease Control and PrevenHon, 2020, Hamady et al., 2022) . In this respect, comparing the seroprevalences reported here with the current situaHon ajer/during the Omicron variants wave could provide important informaHon, if using idenHcal tools complemenHng the analysis with neutralising acHviHes against Omicron and previous variants in these sera. All authors declare that they don't have a conflict of interest regarding the publicaHon of this study. Financial support has been provided by Deutscher Akademischer Austauschdienst (DAAD, PAGEL program, project MENTION to SK, University Bremen, and SSS, State University Zanzibar) and EU (Erasmus+ InternaHonal mobility program to University Bremen). The funding agencies had no influence on the study design, collecHon, analysis or interpretaHon of the data; they were not involved on the decision to submit the manuscript. The study has been carried out in accordance with The Code of Ethics of the World Medical AssociaHon (DeclaraHon of Helsinki) for experiments involving humans and was approved by The Second Vice President Office and The Ministry of Health Zanzibar through the Zanzibar Medical Research and Ethics Commioee (ZAMREC/0001/AUGUST/013). Authors are grateful to all parHcipants for their invaluable contribuHon as well as to all Shehas of the parHcipaHng wards for their the support. We highly appreciate the restless technical support by Petra Berger and all members of the Unguja and Pemba survey teams. The authors acknowledge very much the efforts of the Public Health Laboratory, Pemba, the Zanzibar Health Research InsHtute, and the Ministry of Health for their essenHal support, which they devoted for successful compleHon of this study. 3 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 26, 2022. ; https://doi.org/10.1101/2022.04.23.22274199 doi: medRxiv preprint Table 1. Regional seroprevalences; total number of tests conducted in Unguja and Pemba and their respec#ve districts with seroposi#vity in percent. Global seroprevalence of SARS-CoV-2 anHbodies: A systemaHc review and meta-analysis Performance of the EUROIMMUN AnH-SARS-CoV-2 ELISA Assay for detecHon of IgA and IgG anHbodies in South Africa Waning anHbody responses in COVID-19: what can we learn from the analysis of other coronaviruses? SARS-CoV-2 infecHon in Africa: A systemaHc review and meta-analysis of standardised seroprevalence studies Zanzibar kicks of Covid-19 vaccinaHon, orders another consignment. The CiHzen Hebestreit A. Design, response rates, and popula-Hon: characterisHcs of a cross-secHonal study in Zanzibar Herd immunity, lockdowns and COVID-19 , WHO COVID-19) Dashboard Wete (Pemba)